ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

More information about the Novartis ESG practices is available at https://www.novartis.com/investors/environmental-social-and-governance

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com 


 
Antonio Ligi                          Katerina Kontzalis 
 Novartis External Communications      Corp. Affairs & Global Health Communications 
 +41 79 723 3681 (mobile)              +41 79 797 8393 (mobile) 
 antonio.ligi@novartis.com             katerina.kontzalis@novartis.com 
 Julie Masow 
 Novartis US External Communications 
 +1 862 579 8456 
 julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com 


 
Central                                  North America 
Samir Shah              +41 61 324 7944  Sloan Simpson  +1 862 778 5052 
Thomas Hungerbuehler   +41 61 324 8425 
 Isabella Zinck         +41 61 324 7188

(END) Dow Jones Newswires

September 30, 2021 01:15 ET (05:15 GMT)